RT Journal Article
SR Electronic
T1 High Serum CA19-9 Concentration Indicates High Chemosensitivity and Better Survival in Advanced Urothelial Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 375
OP 380
DO 10.21873/anticanres.13122
VO 39
IS 1
A1 YAEGASHI, HIROSHI
A1 IZUMI, KOUJI
A1 KADOMOTO, SUGURU
A1 NAITO, RENATO
A1 MAKINO, TOMOYUKI
A1 IWAMOTO, HIROAKI
A1 NOHARA, TAKAHIRO
A1 SHIGEHARA, KAZUYOSHI
A1 KADONO, YOSHIFUMI
A1 MIZOKAMI, ATSUSHI
YR 2019
UL http://ar.iiarjournals.org/content/39/1/375.abstract
AB Background: The present study was conducted to investigate whether baseline serum carbohydrate antigen (CA) 19-9 predicts prognosis or treatment effect in patients with advanced urothelial carcinoma (UC). Materials and Methods: We retrospectively analyzed data of patients diagnosed with locally advanced or metastatic or recurrent UC between April 2008 and November 2014. CA19-9 was determined using enzyme-linked immunosorbent assay (ELISA) and the relationship between CA19-9 and prognosis were analyzed. Results: Of 40 patients, seven with CA19-9 ≤2 U/ml who were suspected of having Lewis A-negative blood type and two patients with advanced metastatic liver disease were excluded. UC-specific survival in metastatic disease significantly correlated with prognosis (p=0.018). Overall survival in patients with high serum CA19-9 demonstrated a significantly better prognosis than in those with low concentrations (log-rank test, p=0.032). Conclusion: High baseline serum CA19-9 may predict a good prognosis in patients with advanced UC.